Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors

References

• Aller SG, Yu J, Ward A, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–22
   PubMed Web of Science ®Google Scholar
• Benet LZ. (2009). The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6:1631–43
   PubMed Web of Science ®Google Scholar
• Chang C, Bahadduri PM, Polli JE, et al. (2006). Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976–84
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Yu H, et al. (2012). Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 17:343–51
   PubMed Web of Science ®Google Scholar
• Chiba P, Ecker G, Schmid D, et al. (1996). Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 49:1122–30
   PubMed Web of Science ®Google Scholar
• Chiba P, Hitzler M, Richter E, et al. (1997). Studies on propafenone-type modulators of multidrug resistance III: variations on the nitrogen. Quant Struct-Act Relat 16:361–6
   Web of Science ®Google Scholar
• Colabufo NA, Berardi F, Cantore M, et al. (2008). Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem 16:362–73
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Cao J, et al. (1996). Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171–9
   PubMed Web of Science ®Google Scholar
• Dolghih E, Bryant C, Renslo AR, Jacobson MP (2011). Predicting binding to p-glycoprotein by flexible receptor docking. PLoS Comput Biol 7:e1002083
   PubMed Web of Science ®Google Scholar
• Ekins S, Kim RB, Leake BF, et al. (2002). Three-dimensional quantitative structure--activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964–73
   PubMed Web of Science ®Google Scholar
• Ford JM, Bruggemann EP, Pastan I, et al. (1990). Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–56
   PubMedGoogle Scholar
• Ford JM, Prozialeck WC, Hait WN. (1989). Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35:105–15
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69–74
   PubMed Web of Science ®Google Scholar
• Gatlik-Landwojtowicz E, Aänismaa P, Seelig A. (2006). Quantification and characterization of P-glycoprotein--substrate interactions. Biochemistry 45:3020–32
   PubMed Web of Science ®Google Scholar
• Globisch C, Pajeva IK, Wiese M. (2006). Structure--activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg Med Chem 14:1588–98
   PubMed Web of Science ®Google Scholar
• Hochman J, Mei Q, Yamazaki M, et al. (2006). Role of mechanistic transport studies in lead optimization. In: Borchardt RT, Kerns EH, Hageman MJ, et al., eds. Optimizing the “drug-like” properties of leads in drug discovery. New York: Springer, 25–48
   Google Scholar
• Jabeen I, Pleban K, Rinner U, et al. (2012). Structure--activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. J Med Chem 55:3261–73
   PubMed Web of Science ®Google Scholar
• Kim KH. (2001). 3D-QSAR analysis of 2,4,5- and 2,3,4,5-substituted imidazoles as potent and nontoxic modulators of P-glycoprotein mediated MDR. Bioorg Med Chem 9:1517–23
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–94
   PubMed Web of Science ®Google Scholar
• Klepsch F, Chiba P, Ecker GF. (2011). Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol 7:e1002036
   Google Scholar
• Lagunin A, Gloriozova T, Dmitriev A, et al. (2013). Computer evaluation of drug interactions with P-glycoprotein. Bull Exp Biol Med 154:521–4
   PubMedGoogle Scholar
• Lam FC, Liu R, Lu P, et al. (2001). Beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121–8
   PubMed Web of Science ®Google Scholar
• Langer T, Eder M, Hoffmann RD, et al. (2004). Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) 337:317–27
   PubMed Web of Science ®Google Scholar
• Lee JY, Urbatsch IL, Senior AE, Wilkens S. (2008). Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. J Biol Chem 283:5769–79
   PubMed Web of Science ®Google Scholar
• Leong MK, Chen HB, Shih YH. (2012). Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning scheme. PLoS One 7:e33829
   PubMedGoogle Scholar
• Ling V, Kartner N, Sudo T, et al. (1983). Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67:869–74
   PubMedGoogle Scholar
• Locher KP. (2009). Structure and mechanism of ATP-binding cassette transporters. Philos Trans R Soc Lond B Biol Sci 364:239–45
   PubMed Web of Science ®Google Scholar
• Longley DB, Johnston PG. (2005). Molecular mechanisms of drug resistance. J Pathol 205:275–92
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. (2003). Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278:39706–10
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Higgins CF, et al. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624–32
   PubMed Web of Science ®Google Scholar
• Müller H, Pajeva IK, Globisch C, Wiese M. (2008). Functional assay and structure--activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem 16:2448–62
   PubMed Web of Science ®Google Scholar
• Oldham ML, Davidson AL, Chen J. (2008). Structural insights into ABC transporter mechanism. Curr Opin Struct Biol 18:726–33
   PubMed Web of Science ®Google Scholar
• Pajeva I, Wiese M. (1998). Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J Med Chem 41:1815–26
   PubMed Web of Science ®Google Scholar
• Pajeva IK, Globisch C, Wiese M. (2004). Structure--function relationships of multidrug resistance P-glycoprotein. J Med Chem 47:2523–33
   PubMed Web of Science ®Google Scholar
• Pajeva IK, Globisch C, Wiese M. (2009). Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. ChemMedChem 4:1883–96
   PubMed Web of Science ®Google Scholar
• Pajeva IK, Wiese M. (2009). Structure--activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J 11:435–44
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. (2012a). Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. Curr Pharm Des 18:4197–214
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. (2012b). Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 19:1946–2025
   PubMed Web of Science ®Google Scholar
• Pearce HL, Safa AR, Bach NJ, et al. (1989). Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A 86:5128–32
   PubMed Web of Science ®Google Scholar
• Ramachandra M, Ambudkar SV, Chen D, et al. (1998). Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37:5010–19
   PubMed Web of Science ®Google Scholar
• Ramu A, Ramu N. (1992). Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30:165–73
   PubMed Web of Science ®Google Scholar
• Raviv Y, Pollard HB, Bruggemann EP, et al. (1990). Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975–80
   PubMed Web of Science ®Google Scholar
• Roe M, Folkes A, Ashworth P, et al. (1999). Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9:595–600
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Kamis AB, Callaghan R, et al. (2003). Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278:8294–9
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Velarde G, Ford RC, et al. (2001). Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20:5615–25
   PubMed Web of Science ®Google Scholar
• Salphati L. (2009). Transport-metabolism interplay. Mol Pharm 6:1629–30
   PubMedGoogle Scholar
• Sarshar S, Zhang C, Moran EJ, et al. (2000). 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 1. Bioorg Med Chem Lett 10:2599–601
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Ambudkar SV. (2007). About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6:13–23
   PubMed Web of Science ®Google Scholar
• Schinkel AH. (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179–94
   PubMed Web of Science ®Google Scholar
• Schmid D, Ecker G, Kopp S, et al. (1999). Structure--activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol 58:1447–56
   PubMed Web of Science ®Google Scholar
• Seelig A, Landwojtowicz E. (2000). Structure--activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31–40
   PubMed Web of Science ®Google Scholar
• Sharom FJ. (2008). ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:105–27
   PubMed Web of Science ®Google Scholar
• Sharom FJ. (2011). The P-glycoprotein multidrug transporter. Essays Biochem 50:161–78
   PubMed Web of Science ®Google Scholar
• Stępień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. (2012). The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 64:1011–19
   PubMed Web of Science ®Google Scholar
• Tombline G, Muharemagić A, White LB, Senior AE. (2005). Involvement of the “occluded nucleotide conformation” of P-glycoprotein in the catalytic pathway. Biochemistry 44:12879–86
   PubMedGoogle Scholar
• Tsakovska IM. (2003). QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells. Bioorg Med Chem 11:2889–99
   PubMed Web of Science ®Google Scholar
• Wang S, Ryder H, Pretswell I, et al. (2002). Studies on quinazolinones as dual inhibitors of P-gp and MRP1 in multidrug resistance. Bioorg Med Chem Lett 12:571–4
   PubMed Web of Science ®Google Scholar
• Weiss J, Dormann SM, Martin-Facklam M, et al. (2003). Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197–204
   PubMed Web of Science ®Google Scholar
• Zamora JM, Pearce HL, Beck WT. (1988). Physical--chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454–62
   PubMed Web of Science ®Google Scholar
• Zhang C, Sarshar S, Moran EJ, et al. (2000). 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2. Bioorg Med Chem Lett 10:2603–5
   PubMedGoogle Scholar